trientine hydrochloride

MOA-728 is a code name used by Bausch Health for investigational formulations of trientine hydrochloride, a copper-chelating agent primarily indicated for the treatment of Wilson's disease. Wilson's disease is a rare genetic disorder characterized by the toxic accumulation of copper in the liver, brain, and other vital organs due to mutations in the ATP7B gene. Trientine works as a polyamine chelator that binds to systemic copper ions, forming a stable, water-soluble complex that is subsequently excreted through the kidneys. While trientine is traditionally administered as an oral medication (marketed by Bausch Health as Syprine), the MOA-728 development program has explored new formulations, including a room-temperature stable oral version and an intravenous (IV) formulation. The IV formulation is being evaluated in Phase 1 clinical trials to provide an alternative administration route for patients who cannot tolerate oral therapy or require rapid reduction of copper levels.

Brand names

Syprine

Other names

triethylenetetramine dihydrochlorideTETAtrientine